ZyVersa Therapeutics Expands Efforts to Combat Obesity Complications With New Advisory Board
ZyVersa Therapeutics Expands Efforts to Combat Obesity Complications With New Advisory Board
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or "ZyVersa"))))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces a new SAB to support advancement of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. Based on its mechanism of action, IC 100, in combination with incretin therapy, is anticipated to augment weight loss, but more importantly, to attenuate the chronic systemic inflammation leading to metabolic complications and other inflammatory comorbidities of obesity.
ZyVersa Therapeutics, Inc.（纳斯达克：ZVSA，或"ZyVersa"）是一家临床阶段的专业生物制药公司，专注于开发治疗炎症和肾脏疾病的首创药物，宣布推出一项新的 SAb，以支持 Inflammasome ASC 抑制剂 IC 100 用于肥胖合并代谢并发症的进展。根据其作用机制，IC 100 与肠促素治疗结合预计可以增加体重减轻，更重要的是，可以减轻导致代谢并发症和其他肥胖相关炎症并发症的慢性全身性炎症。
